Free Trial
NASDAQ:EXAI

Exscientia (EXAI) Stock Price, News & Analysis

$4.69
-0.04 (-0.85%)
(As of 05/24/2024 ET)
Today's Range
$4.67
$4.87
50-Day Range
$3.99
$6.86
52-Week Range
$3.86
$9.12
Volume
382,620 shs
Average Volume
528,079 shs
Market Capitalization
$566.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75

Exscientia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
107.9% Upside
$9.75 Price Target
Short Interest
Bearish
3.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Exscientia in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.07) to ($1.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.50 out of 5 stars

Medical Sector

686th out of 917 stocks

Biological Products, Except Diagnostic Industry

108th out of 154 stocks

EXAI stock logo

About Exscientia Stock (NASDAQ:EXAI)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

EXAI Stock Price History

EXAI Stock News Headlines

Exscientia (NASDAQ:EXAI) Shares Gap Down to $4.95
Exscientia Business Update for First Quarter 2024
Exscientia Q1 2024 Earnings Preview
See More Headlines
Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
5/25/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:EXAI
Fax
N/A
Employees
483
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$13.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+107.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-181,560,000.00
Net Margins
-666.80%
Pretax Margin
-737.98%

Debt

Sales & Book Value

Annual Sales
$25.60 million
Book Value
$3.47 per share

Miscellaneous

Free Float
101,062,000
Market Cap
$566.97 million
Optionable
Optionable
Beta
0.82
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. David Hallett Ph.D. (Age 55)
    Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
  • Mr. Ben R. Taylor (Age 47)
    CFO, Chief Strategy Officer & Executive Director
    Comp: $534.97k
  • Dr. Michael Krams M.D. (Age 63)
    Chief Medical Officer
  • Ms. Eileen Jennings-Brown
    Chief Information Officer
  • Ms. Sara Sherman
    Vice President of Investor Relations
  • Mr. Dan Ireland
    Executive VP of Legal & Company Secretary
  • Mr. Parker Moss
    Executive Vice President of Corporate Development
  • Ms. Caroline Rowland
    Chief People Officer
  • Mr. Richard Law
    Chief Business Officer
  • Dr. John P. Overington Ph.D.
    Chief Data Officer

EXAI Stock Analysis - Frequently Asked Questions

Should I buy or sell Exscientia stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXAI shares.
View EXAI analyst ratings
or view top-rated stocks.

What is Exscientia's stock price target for 2024?

4 Wall Street research analysts have issued 1 year price targets for Exscientia's stock. Their EXAI share price targets range from $7.00 to $13.00. On average, they predict the company's share price to reach $9.75 in the next year. This suggests a possible upside of 107.9% from the stock's current price.
View analysts price targets for EXAI
or view top-rated stocks among Wall Street analysts.

How have EXAI shares performed in 2024?

Exscientia's stock was trading at $6.41 at the start of the year. Since then, EXAI stock has decreased by 26.8% and is now trading at $4.69.
View the best growth stocks for 2024 here
.

When is Exscientia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our EXAI earnings forecast
.

How were Exscientia's earnings last quarter?

Exscientia plc (NASDAQ:EXAI) issued its earnings results on Thursday, March, 21st. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. The business earned $3.10 million during the quarter, compared to analyst estimates of $41.63 million. Exscientia had a negative trailing twelve-month return on equity of 34.59% and a negative net margin of 666.80%.

What ETF holds Exscientia's stock?

First Trust Nasdaq Artificial Intelligence and Robotics ETF holds 1,443,583 shares of EXAI stock, representing 1.32% of its portfolio.

When did Exscientia IPO?

Exscientia (EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at $20.00-$22.00 per share.

Who are Exscientia's major shareholders?

Exscientia's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.78%), Platinum Investment Management Ltd. (3.26%), Mitsubishi UFJ Trust & Banking Corp (0.13%), Susquehanna Portfolio Strategies LLC (0.03%), EntryPoint Capital LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.01%).

How do I buy shares of Exscientia?

Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EXAI) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners